What is GRAL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.28B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GRAL?

P/E (TTM) is n/a and 52-week range is $41.50 to $166.47 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GRAL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GRAL?

The company profile lists revenue (TTM) near $165M, net income (TTM) near $-38.98B, EPS (TTM) near $-9.75 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Grail Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Menlo Park, California, US, 42.9M shares outstanding, ISIN US3847471014 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Grail Inc

$GRAL

Health Care · Biotechnology

Run Scenarios

$140.58

+6.01%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 910 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Employees

910

Website

grail.com/

IPO

2024-06-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)